ARTL — Artelo Biosciences Cashflow Statement
0.000.00%
- $3.41m
- $1.07m
Annual cashflow statement for Artelo Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 August 31st | 2021 August 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -4.65 | -7.44 | -10.1 | -9.29 | -9.83 |
Depreciation | |||||
Non-Cash Items | 0.348 | 1.54 | 2.29 | 0.419 | 0.569 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -0.041 | -0.244 | -0.215 | 0.663 | 0.907 |
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -4.35 | -6.14 | -8.01 | -8.21 | -8.35 |
Capital Expenditures | 0 | — | — | — | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | — | -3.44 | 2.96 | 3.51 | 7.77 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 0 | -3.44 | 2.96 | 3.51 | 7.77 |
Financing Cash Flow Items | 0.003 | -0.007 | 0 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 1.98 | 14.1 | 0 | 0.567 | 0.112 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -2.28 | 4.49 | -5.27 | -4.07 | -0.477 |